MedTrace Logo

Inhibiting COMT in Parkinson's Disease

NCT02070887 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-01-25

No results posted yet for this study

Summary

The overall aim of this observational study is to investigate the impact of COMT inhibition on homocysteine metabolism, vascular physiology and correlates of neurodegeneration in PD patients with certain COMT genotype. It is designed to evaluate effect size of Hcy lowering to secondary outcome parameters. Assessment of outcome parameters will be rater-blinded or computer-based.

Conditions

Sponsors & Collaborators

  • Christian Baumann

    lead OTHER

Principal Investigators

  • Christian Baumann, MD · University Hospital Zurich, Division of Neurology

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070887 on ClinicalTrials.gov